Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 53 | Vintage Vibes

Covid vaccine: Pfizer says three doses enough to protect children under 5

Three doses of Pfizer’s Covid-19 vaccine will offer strong protection for children younger than 5, the company announced on Monday.

Evening Standard

If Pfizer's data pans out, when will little kids get the COVID-19 vaccine?

Pfizer plans to submit new data to the Food and Drug Administration this week, bringing families with young children one step closer to a long-awaited vaccine.

WEKU

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

Reuters

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

The Independent UK

Pfizer says COVID vaccine more than 80% effective in kids under 5

Pfizer reported three doses of its vaccine in kids under five produced a strong immune response and was safe.

Axios

Coronavirus FAQ: I took Paxlovid. I felt better. Then symptoms rebounded. What's up?

The antiviral drug is prescribed to those at risk of severe disease. It's been credited with reducing hospitalizations. But then there's the "Paxlovid rebound."

WEKU

This Is What Whales Are Betting On Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years

The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX). Following the recommendation, many of the nation's doctors, pharmacies, and other vaccination sites are expected to begin offering the extra doses to the 28 million U.S. children…

Benzinga

High blood pressure tablets recalled in Scotland amid 'impurity' concerns

Twelve batches of Pfizer Accupro have been removed from the shelves.

Daily Record

The CDC is urging a Pfizer booster for children ages 5 to 11

The Centers for Disease Control and Prevention's advice opens a third COVID-19 shot to healthy elementary-age kids — just like what is already recommended for everybody 12 and older.

WEKU

US panel recommends COVID booster jab for children aged 5 to 11

Just more than 29 percent of US children in the age group have received two doses of Pfizer-BioNTech’s vaccine to date.

Al Jazeera

CDC experts recommend COVID vaccine boosters for kids 5-11

The Centers for Disease Control and Prevention’s vaccine expert panel Thursday recommended kids 5-11 get a third shot of Pfizer’s COVID-19 vaccine as a booster five months after their last dose, which once adopted by the agency clears the way for pharmacies and health care providers to begin offering the…

Tribune News Service

CDC advisers urge Pfizer booster for children ages 5 to 11

U.S. health advisers are urging a booster dose of Pfizer's COVID-19 vaccine for kids ages 5 to 11

The Independent UK

Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections

The U.S. National Institutes of Health and Pfizer Inc (NYSE:PFE) are discussing testing a longer course of COVID-19 antiviral treatment Paxlovid, required to prevent reinfections, White House Chief Medical Officer Anthony Fauci said. "We're going to be planning what studies we're going to be doing relatively soon, within the next few days," to…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Read Why Pfizer Is Limiting Supply Of Paxlovid For Combination Studies: Bloomberg

Amid rising concerns over the potential development of resistance to Pfizer Inc's (NYSE:PFE) COVID-19 pill Paxlovid, the company has declined to supply researchers with the antiviral for use in combination studies, according to a Bloomberg report. Researchers say that Paxlovid combined with other drugs might stave off resistance. Pfizer hasn't started any combination…

The Guardian - UK

At least 25m people in UK to be offered COVID booster this autumn

Vaccine body says extra jab will be for most vulnerable adults, frontline social care and health workers

Benzinga

Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics

It’s been a long and arduous road for Revive Therapeutics Ltd. (OTC: RVVTF) regarding their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.

Benzinga

Looking At Pfizer's Recent Whale Trades

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

Heartbroken family of man take legal action after he died of blood clots two weeks after getting AstraZeneca jab

Jack Hurn had just bought his first home with his partner, and was planning on proposing to her

Tribune News Service

Q&A: A parents’ guide to COVID booster shots for kids 5-11

SAN JOSE, Calif. -- With COVID-19 cases rising again in the Bay Area, parents have a new consideration for protecting their children this week: The Food and Drug Administration granted emergency use authorization Tuesday for kids ages 5-11 to get a booster shot of Pfizer’s COVID-19 vaccine.

Daily Mirror

Ex-student, 31, died from blood clots in the brain two weeks after Covid jab

Jack Hurn from Redditch received first dose of AstraZeneca vaccine but died 11 days later in hospital from blood clots on his brain

The Guardian - US

A million have died of Covid-19 in America. How did this happen?

One million people should never have to die from another pandemic. Not in America, a country built to do so much better

Reuters

From storage to transport, hurdles to getting COVID vaccine to N.Koreans

As North Korea battles its first known COVID outbreak, a lack of storage, chronic power shortages and inadequately trained medical staff pose acute challenges to inoculating its 25 million people - even with outside help, analysts said.

The Hindu

India’s ‘other’ COVID vaccines: The status of under-trial, approved and unused jabs

While Covishield and Covaxin lead the Covid-19 vaccination effort in India, other vaccines, too, are under development or remain unused after approval from the Centre

Los Angeles Times

With old-school technology, can Novavax win over COVID vaccine skeptics?

Since their debut just 18 months ago, three COVID-19 vaccines have saved an estimated 2.2 million American lives, changed the trajectory of a pandemic and inspired all manner of conspiracy theories.

1 … 52 53 54 55

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

348 stories

PFE

346 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.